Cited by 39Bipolar Disorder and TreatmentTreatment of Major DepressionPersonality Disorders and Psychopathology

Lamotrigine as add‐on treatment to lithium and divalproex: lessons learned from a double‐blind, placebo‐controlled trial in rapid‐cycling bipolar disorder

Open access
Kemp, David E, Gao, Keming, Fein, Elizabeth B, Chan, Philip K, Conroy, Carla, Obral, Sarah, Ganocy, Stephen J, Calabrese, Joseph R·2012·Bipolar Disorders

Abstract

Kemp DE, Gao K, Fein EB, Chan PK, Conroy C, Obral S, Ganocy SJ, Calabrese JR. Lamotrigine as add‐on treatment to lithium and divalproex: lessons learned from a double‐blind, placebo‐controlled trial in rapid‐cycling bipolar disorder. Bipolar Disord 2012: 14: 780–789. © 2012 John Wiley & Sons A/S. Objectives: A substantial portion of the morbidity associated with rapid‐cycling bipolar disorder (RCBD) stems from refractory depression. This study assessed the antidepressant effects of lamotrigine as compared with placebo when used as add‐on therapy for rapid‐cycling bipolar depression non‐responsive to the combination of lithium plus divalproex. Methods: During Phase 1 of this trial, hypomanic, manic, mixed, and/or depressed outpatients (n = 133) aged 18–65 years with DSM–IV RCBD type I or II were initially treated with the open combination of lithium and divalproex for up to 16 weeks. During Phase 2, subjects who did not meet the criteria for stabilization (n = 49) (i.e., remained in or cycled into the depressed phase) were randomly assigned to double‐blind, adjunctive lamotrigine (n = 23) or adjunctive placebo (n = 26). The primary endpoint was the mean change in depression symptom severity from the beginning of Phase 2 to the end of Phase 2 (week 12) on the Montgomery‐Åsberg Depression Rating Scale (MADRS) total score. Data were analyzed by analysis of covariance with last observation carried forward and a mixed‐models analysis. Results: During Phase 1, a high rate of study discontinuations occurred due to intolerable side effects (13/133; 10%) and study non‐adherence (22/133; 17%). Only 14% (19/133) stabilized on the open combination of lithium and divalproex. Among the 49 (37%) patients randomized to the double‐blind adjunctive treatment phase, mean ± standard error change from baseline on the MADRS total score was −8.5 ± 1.7 points for lamotrigine and −9.1 ± 1.5 points for placebo (p = not significant; mixed‐models analysis). No significant differences were observed in the rates of response, remission, or bimodal response between lamotrigine and placebo. Conclusions: The poor tolerability, lack of efficacy, and high rate of early discontinuation with the combination of lithium and divalproex suggests this regimen was ineffective for the majority of patients with RCBD. Among patients who did not stabilize on lithium and divalproex, the addition of lamotrigine was no more effective than placebo in reducing depression severity. The findings suggest an opportunity for several design modifications to enhance signal detection in future trials of RCBD. The main limitation is the small number of subjects randomized to double‐blind treatment.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/bdi.12013

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. [22]First MB Spitzer RL Gibbon M Structured clinical interview for DSM-IV axis I disorder-patient edition (SCID-I/P, Version 2.0, 4/97 revision) New York New York State Psychiatric Institute 1997

Cited by

Sorted by citations

Authors
Kemp, D. E., Gao, K., Fein, E. B., Chan, P. K., Conroy, C., Obral, S., Ganocy, S. J., & Calabrese, J. R.
Affiliations
University Hospitals Cleveland Medical Center (US)
Corresponding author
Kemp, David E
Venue
Bipolar Disorders
Publisher
Wiley
Published
2012-10-29
Volume
14
Issue
7
Pages
780-789
ISSN
  • 1398-5647 (ISSN-L)
  • 1399-5618
OpenAlex
W2128560634
Cited by
39
References
43
Citations by year
2026: 1 · 2025: 4 · 2024: 2 · 2023: 1 · 2022: 5 · 2021: 3 · 2019: 7 · 2018: 2 · 2017: 2 · 2016: 4 · 2015: 2 · 2014: 3 · 2013: 2 · 2012: 1
FWCI
1.82
Type
journal article
Language
en
Open access
Locations
  • Bipolar Disorders (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • Eli Lilly and Company
  • Pfizer
  • AstraZeneca
  • Sanofi
  • Stanley Medical Research Institute
  • Case Western Reserve University
  • National Institutes of Health (5kl2rr024990-05)
  • National Institute of Mental Health (R21MH-62650, R21MH062650)
  • National Center for Research Resources (KL2-RR-024990, 1KL2 RR024990)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
  • Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
  • Social Sciences › Psychology › Clinical Psychology › Personality Disorders and Psychopathology
Keywords
lamotrigine, rapid cycling bipolar disorder, bipolar depression, adjunctive therapy, lithium, divalproex, treatment-resistant depression, drug tolerability, treatment discontinuation, bimodal response, Montgomery-Asberg Depression Rating Scale, mixed states
MeSH terms
Lamotrigine, Adolescent, Adult, Aged, Bipolar Disorder, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Psychiatric Status Rating Scales, Retrospective Studies, Triazines, Valproic Acid, Lithium Chloride, Antimanic Agents, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review